Detailansicht

Wissensnetz

Person

Sascha Dietrich (1979-)

Arzt

Name	Sascha Dietrich
Zeit	1979- (Lebensdaten)
Ort	Dresden (Geburtsort) Heidelberg (Wirkungsort) Deutschland
Akademischer Grad bzw. Titel	Univ.-Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf)
Variante	Sasha Dietrich (falsche Namensform)
Beziehung	Universität Heidelberg. Klinikum Universitätsklinikum Heidelberg. Zentrum für Innere Medizin Universitätsklinikum Düsseldorf
Weitere Angaben	Diss. Fachbereich Medizin; Oberarzt, Hämatologische Ambulanz, Medizinische Klinik V, Universitätsklinikum Heidelberg
Quelle	AM Metadaten
Datensatztyp	Person
GND-Nummer	136406300
Datensatz-ID	136406300
Beteiligt an alle anzeigen Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs) Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas Reversible Host–Guest Crosslinks in Supramolecular Hydrogels for On‐Demand Mechanical Stimulation of Human Mesenchymal Stem Cells Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia Functional analysis of structural variants in single cells using Strand-seq Proteogenomics refines the molecular classification of chronic lymphocytic leukemia Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation Nutzen der Iodkarte in der spektralen CT zur Unterscheidung von malignen und benignen Brustraumforderungen Nutzen der Iodkarte in der spektralen CT zur Unterscheidung von malignen und benignen Brustraumforderungen Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma Axicabtagen-Ciloleucel (Yescarta) : CAR-T-Zellen bei der aggressiven B-Zell-Lymphomen DLBCL und PMBCL Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party Multi‐Omics Factor Analysis—a framework for unsupervised integration of multi‐omics data sets Drug-perturbation-based stratification of blood cancer Haarzell-Leukämie A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma Early Prediction of Therapy Outcome in Patients with High-Risk Soft Tissue Sarcoma Using Positron Emission Tomography Fluoreszenzindikatoren für intrazelluläre Natriumkonzentrationsmessungen Fluoreszenzindikatoren für intrazelluläre Natriumkonzentrationsmessungen

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Sascha Dietrich (1979-)

Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases

Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL

Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs)

Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification

A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Reversible Host–Guest Crosslinks in Supramolecular Hydrogels for On‐Demand Mechanical Stimulation of Human Mesenchymal Stem Cells

Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia

Functional analysis of structural variants in single cells using Strand-seq

Proteogenomics refines the molecular classification of chronic lymphocytic leukemia

Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation

Nutzen der Iodkarte in der spektralen CT zur Unterscheidung von malignen und benignen Brustraumforderungen

Nutzen der Iodkarte in der spektralen CT zur Unterscheidung von malignen und benignen Brustraumforderungen

Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL

EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia

EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia

EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia

EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis

Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma

Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma

Axicabtagen-Ciloleucel (Yescarta) : CAR-T-Zellen bei der aggressiven B-Zell-Lymphomen DLBCL und PMBCL

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party

Multi‐Omics Factor Analysis—a framework for unsupervised integration of multi‐omics data sets

Drug-perturbation-based stratification of blood cancer

Haarzell-Leukämie

A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma

Early Prediction of Therapy Outcome in Patients with High-Risk Soft Tissue Sarcoma Using Positron Emission Tomography

Fluoreszenzindikatoren für intrazelluläre Natriumkonzentrationsmessungen

Fluoreszenzindikatoren für intrazelluläre Natriumkonzentrationsmessungen